Introduction {#s1}
============

Congenital adrenal hyperplasia (CAH) is a group of genetically inherited enzymatic defects of biosynthesis of cortisol and accumulating intermediate precursors. The most common form of CAH is 21-hydroxylase deficiency (21-OHD) ([@r1],[@r2],[@r3],[@r4],[@r5]), which affects about 1 in 18,000 worldwide. 21-OHD is classified into three forms according to the severity of the disease. The most severe form is the salt-wasting (SW) form. In the SW and simple virilizing (SV) forms, affected female neonates present with virilized external genitalia. The nonclassic (NC) form can manifest with hyperandrogenism later in life ([@r3],[@r4],[@r5]). The SW form accounts for approximately 70--80% of all cases of 21-OHD ([@r1], [@r3], [@r5]). In children with the SW form, a life-threatening salt-wasting crisis occurs in the second or third week of life.

Ambiguous genitalia at birth or salt-wasting symptoms such as failure to thrive, and vomiting and skin pigmentation during the neonatal period can lead to the suspicion of 21-OHD. Elevated 17-hydroxyprogesterone (17-OHP) is the best marker for the diagnosis of 21-OHD ([@r3], [@r5]). In addition, patients with the SW form show elevated plasma renin activity or an elevated plasma renin.

As the initial treatment, a high dose of hydrocortisone is administered to rapidly suppress adrenal hyperplasia and excess adrenal androgen ([@r5]). Thereafter, the dose of hydrocortisone is reduced to a maintenance dose, and lifelong treatment is necessary ([@r5]). In infants with the SW form, 9α-fludrocortisone is required in addition to hydrocortisone ([@r3], [@r5]). In childhood, the main targets of treatment of 21-OHD are as follows: 1) normal physical growth, 2) normal development of secondary sex characteristics, and 3) avoidance of adrenal crisis ([@r1],[@r2],[@r3], [@r5]). After reaching adulthood, the transition to an adult endocrinologist is required ([@r3], [@r5],[@r6],[@r7]). As the relationship between metabolic abnormalities and glucocorticoid dose in adult patients with 21-OHD has recently been reported in several studies ([@r8],[@r9],[@r10],[@r11]), pediatricians who care for 21-OHD patients should avoid overdose of glucocorticoid.

Newborn Mass Screening (MS) for CAH {#s2}
===================================

The purposes of MS for CAH are prevention of death caused by adrenal insufficiency in neonates with the SW form and gender misassignment of 46,XX female neonates with the SW and SV forms ([@r3], [@r5], [@r12],[@r13],[@r14]). MS for CAH was first reported in 1977 ([@r15]), and since then, MS for CAH has been implemented in at least 30 countries ([@r9], [@r14], [@r16],[@r17],[@r18],[@r19],[@r20],[@r21],[@r22],[@r23]). However, CAH screening is associated with a high false positive rate (FPR) and low positive predictive value (PPV), especially in preterm infants ([@r3], [@r5], [@r8], [@r24],[@r25],[@r26]). Moreover, as affected girls with the SW and SV forms show virilized genitalia at birth, clinical diagnosis is thought to be easy ([@r26]). Based on these points of view, several countries do not perform MS for CAH ([@r27], [@r28]).

In 2012, the efficiency of neonatal screening for CAH in France from 1996 to 2003 was reported ([@r26]). In their study, a total of 6,012,798 neonates were screened and 15,407 were positive on screening for CAH. However, among these cases, only 370 were ultimately diagnosed as having CAH. Among them, family history led to the diagnosis of CAH in 74 infants, and in 96 girls with CAH, ambiguous genitalia were identified during neonatal examination. In addition, 13 boys were clinically diagnosed as having CAH before obtaining the results of MS. Therefore, in these 183 patients (about half of the total number of patients with CAH), MS for CAH was not beneficial. Moreover, among 38 premature neonates with positive screening results, MS was useful for the diagnosis of CAH in 13 infants, among whom only 6 had the severe SW form. During this period, the sensitivity of MS for CAH was 93.5%, and the PPV was 2.3%. Furthermore, the PPV in preterm infants was only 0.4%.

One of the rationales for MS for CAH is to prevent the death of neonates. In their study, Coulm *et al*. analyzed mortality rates of neonates due to adrenal insufficiency in children younger than 1 yr of age from 1979 to 2007 ([@r26]). The mortality rate of adrenal diseases from 1979 to 1984 was 0.10 per 100,000 births. From 1985 to 1990, it increased to 0.20 per 100,000 births. From 1991 to 1995, it decreased to about 0. 09 per 100,000 births, and from 1991 to 1995, it was about 0.08 per 100,000 births. Therefore, most of the decrease was observed in 1991--1995. As nationwide MS for CAH began in 1996 in France, decrease of the mortality rate was not associated with the screening.

In the UK, CAH is not included in newborn mass screening. Khalid *et al*. ([@r28]) reported clinical features of congenital adrenal hyperplasia in the UK. Approximately 90% of CAH patients were diagnosed before one year of age. Most girls were diagnosed by virilization of external genitalia, and about 20% of patients with CAH presented with salt-wasting crisis on or after 14 days of age. Therefore, MS for CAH could have prevented salt-wasting crisis in these 20% of patients with CAH.

Gidlof *et al*. ([@r22]) reported the results of the nationwide MS for CAH in Sweden over a 26-yr period, which is the longest study period so far. They concluded that MS for CAH is highly effective in detecting SW and therefore in reducing mortality.During the 26-yr period, almost all infants born from 1986 to 2011 (2,737,932 newborns) were subjected to screening. A total of 143 patients with SW were identified. The sensitivity of MS for CAH was 84.3%, and the specificity was 99.9%. The total recall rate was 0.06%. However, the recall rate in preterm infants (0.57%) was significantly higher than that in term infants (0.03%). The PPV in term infants was 25%. On the other hand, the PPV in preterm infants was 1.4% despite gestational age-related cutoff levels.

The difference in opinion regarding MS for CAH may be related to the way of thinking about prevention of SW crisis, health administration, and finance of health administration.

Liquid Chromatography-tandem Mass Spectrometry (LC-MS/MS) in MS for CAH {#s3}
=======================================================================

LC-MS/MS is now being incorporated in newborn screening laboratories in several countries. A method of performing a steroid-profiling assay for simultaneous analysis of 17-hydroxyprogesterone, androstenedione (4-AD), 21-deoxycortisol (21-DOF), 11-deoxycortisol (11-DOF) and cortisol has been reported ([@r29],[@r30],[@r31],[@r32],[@r33],[@r34],[@r35],[@r36]). Performance of a steroid-profiling assay by LC-MS/MS as a second-tier test in MS for CAH may avoid unnecessary recalls, reduce the FPR and increase the PPV.

Minnesota, USA a two-tier protocol in which a second-tier test was performed using LC-MS/MS to measure the levels of 17-OHP, 4-AD, and cortisol simultaneously in blood filter papers was started in 2004, and the efficiency of the second-tier steroid test using LC-MS/MS has been reported ([@r33]). From 1999 to 2004, a one-tier protocol had been used. In the one-tier protocol, the 17-OHP level was measured by immunoassay, and weight-based cutoff values were employed. From 2004, following two-tier screening protocol was employed: If the 17-OHP level was above the cutoff level in the first-tier test using an immunoassay, the filter paper was automatically analyzed by LC-MS/MS as a second-tier test. The cutoff levels of the blood 17-OHP level and the ratio of (17-OHP+4-AD)/cortisol in the two-tier test are summarized in [Table 1](#tbl_001){ref-type="table"}Table 1Cutoff levels of LC-MS/MS in the second-tier test. From 2004 to 2008, various cutoff values and analytes were used in the second-tier steroid-profiling assay. From 2008, gender-specific reference ranges of 17-OHP were used because girls had lower 17-OHP levels ([@r37], [@r38]).

A negative result in the second-tier test \[either a normal 17-OHP level or a normal ratio of (17-OHP+4-AD)/cortisol\] was considered negative. If the second-tier test was positive \[both the 17-OHP level and the ratio of (17-OHP+4-AD)/cortisol were above the cutoff\], the result was presumed to be positive, and the infant was subjected to medical examination.

When using the two-tier protocol, the false negative rate and FPR unexpectedly increased to 32.4% (one-tier protocol, 15.4%) and 0.065% (one-tier protocol, 0.057%), respectively, and the PPV decreased to 8% (one-tier screening, 9.5%), although these changes were not statistically significant. However, the two-tier protocol was effective in reducing the recall for another heel prick. An average of 355 infants per year were recalled in the one-tier protocol, but an average of 30 infants per year were recalled in the two-tier protocol.

In the two-tier protocol for MS, eleven infants were missed. Of them, 3 patients had the SW form, and 8 patients had the SV form. These cases were missed for the following reasons. The blood 17-OHP levels in 7 infants were below the cutoff in the first-tier test. The other four cases showed an increased 17-OHP level in the first-tier test, but the 17-OHP level in one of these four infants was below the cutoff level in the second-tier test. In the remaining three cases, the blood 17-OHP levels were above the cutoff in the second-tier test, but the ratio of (17-OHP +4AD)/cortisol was below the cutoff, and the results of the second-tier tests were presumed to be normal. One reason for the high false negative rate might be due to delayed rise of 17-OHP in some patients with classic 21-OHD ([@r33], [@r34]). In addition, the cutoff levels of 17-OHP and the ratio of (17-OHP +4AD)/cortisol in the second-tier test might be related.

Schwarz *et al*. ([@r32]) reported the results of LC-MS/MS as a second-tier test in MS for CAH from Utah, USA. Over a 13-mo period, 64,615 infants were screened by immunoassay in the first-tier test. A total of 2.6% (1,709) of the infants had a17-OHP level higher than the cutoff value in the first-tier test, and their filter papers were subjected to LC-MS/MS analysis in the second-tier test. The criteria for a positive second-tier test requiring a second blood sample and referral to a pediatric endocrinologist were the presence of both a 17-OHP level of greater than 12.5 ng/ml and a ratio of (17-OHP+4AD) /cortisol greater than 1.0 ([Table 1](#tbl_001){ref-type="table"}). As a result, 64 infants were considered to have a positive result in the second-tier test, and thus they required a second blood spot and referral to a pediatric endocrinologist. Among the infants who had a positive second-tier test, 80% (51/64) had a birth weight of \< 2500 g. Finally, among these 64 infants, 6 infants were diagnosed with 21-OHD. The FPR decreased from 2.6% to 0.09% using LC-MS/MS in the second-tier test, and the PPV improved from 0.4% to 9.4%; however, the FPR was still high in the low birth weight infants.

In Sapporo Japan, steroid profiling from a blood spot by LC-MS/MS has been used as a second-tier test ([@r10], [@r36]). Fujikura *et al*. ([@r36]) reported the one-year results of MS for CAH using LC-MS/MS as a second-tier test since 2011. The two-tier protocol used in Sapporo was as follows ([Table 1](#tbl_001){ref-type="table"}). When the 17-OHP level was ≥ 5.5 ng/ml by immunoassay in the first-tier test, the filter paper was automatically subjected to LC-MS/MS in a second-tier test. If an infant of ≥ 37 weeks of gestational age showed either 1) a 17-OHP level of ≥ 4 ng/ml or 2) a 17-OHP level of ≥ 3 ng/ml and a (17-OHP+4AD)/cortisol ratio of ≥ 0.2 in the second-tier test, the result was considered to be positive, a second heel prick was requested, and the infant was referred to a pediatric endocrinologist. If an infant of \< 37 wk of gestational age showed either 1) a 17-OHP level of ≥ 6 ng/ml or 2) a 17-OHP level of ≥ 5 ng/ml and a (17-OHP+4AD)/cortisol of ≥ 0.2, the result was considered to be positive, a second heel prick was requested, and the infant was referred to a pediatric endocrinologist. During 2009 to 2011, the 17-OHP level was determined by HPLC in the second-tier test, and recall rate was 7.9% among neonates who were born at \< 37 wk of gestation, whereas it was 0.09% among neonates who were born at ≥ 37 wk of gestation ([Table 2](#tbl_002){ref-type="table"}Table 2Results of MS for CAH using LC-MS/MS as a second-tier test in Sapporo) ([@r39]). After the introduction of LC-MS/MS as the second-tier test, the recall rate was 4.0% among neonates who were born at \< 37 wk of gestation, and the recall rate was 0.02% among neonates who were born at ≥ 37 wk of gestation ([Table 2](#tbl_002){ref-type="table"}). These data were obtained over a one-yr period, but the second-tier test using LC-MS/MS is likely to be useful to reduce the recall rate in term and preterm neonates.

LC-MS/MS is now used for neonatal screening of inborn errors of metabolism of amino acids and fatty acids in Japan ([@r40]). In most newborn screening laboratories, LC-MS/MS is part of the basic equipment. However, LC-MS/MS for steroid analysis requires a higher level of laboratory expertise than an immunoassay. In addition, for steroid profiling from dried blood by LC-MS/MS, the equipment requires high sensitivity and more blood spots. Moreover, to determine amino acids and fatty acids and steroid profile simultaneously, further improvement of the LC-MS/MS equipment is needed. If these problems are solved in the future, steroid profiling by LC-MS/MS will be performed throughout Japan.

Conclusion {#s4}
==========

The low PPV of MS for CAH is a major challenge, and MS for CAH is still controversial worldwide. However, MS for CAH enables prevention of the development of salt-wasting symptoms and death in infants with undiagnosed 21-OHD. Several studies suggest that the use of LC-MS/MS as a second-tier test appears to be able to decrease the recall rate, although this method could not completely eliminate the FPR, especially in preterm infants.
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